Rogers J, Oldham M, Fricchione G, Northoff G, Wilson J, Mann S
J Psychopharmacol. 2023; 37(4):327-369.
PMID: 37039129
PMC: 10101189.
DOI: 10.1177/02698811231158232.
Malone K, Saveen S, Stevens C, McNeil S
Cureus. 2022; 14(6):e26328.
PMID: 35911277
PMC: 9311495.
DOI: 10.7759/cureus.26328.
Huang M, Gibson R, Jayaram M, Caroff S
Cochrane Database Syst Rev. 2022; 7:CD013100.
PMID: 35844143
PMC: 9289703.
DOI: 10.1002/14651858.CD013100.pub2.
Tanzer T, Brouard T, Pra S, Warren N, Barras M, Kisely S
Ther Adv Psychopharmacol. 2022; 12:20451253221092931.
PMID: 35633931
PMC: 9136453.
DOI: 10.1177/20451253221092931.
Kitagawa K, So R, Nomura N, Mizuno Y, Misawa F, Kodama M
PLoS One. 2020; 15(6):e0234864.
PMID: 32555706
PMC: 7302491.
DOI: 10.1371/journal.pone.0234864.
Lorazepam-Resistant Catatonia in an Antipsychotic-Naïve 24-Year-Old with Psychotic Symptoms.
Lucchelli J, Kourakou S, Perez de Lucia Bove L, Rodriguez D
Case Rep Psychiatry. 2020; 2020:2469707.
PMID: 32318305
PMC: 7165349.
DOI: 10.1155/2020/2469707.
Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy.
Cotes R, Goldsmith D, Kopelovich S, Lally C, Druss B
Community Ment Health J. 2017; 54(6):699-706.
PMID: 29127560
PMC: 6427065.
DOI: 10.1007/s10597-017-0183-y.
Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country.
Armstrong K, Temmingh H
Braz J Psychiatry. 2017; 39(4):293-301.
PMID: 28177063
PMC: 7111406.
DOI: 10.1590/1516-4446-2016-2015.
A clinical review of the treatment of catatonia.
Sienaert P, Dhossche D, Vancampfort D, De Hert M, Gazdag G
Front Psychiatry. 2014; 5:181.
PMID: 25538636
PMC: 4260674.
DOI: 10.3389/fpsyt.2014.00181.
Safety and tolerability of antipsychotic polypharmacy.
Gallego J, Nielsen J, De Hert M, Kane J, Correll C
Expert Opin Drug Saf. 2012; 11(4):527-42.
PMID: 22563628
PMC: 3384511.
DOI: 10.1517/14740338.2012.683523.
Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.
Gallego J, Bonetti J, Zhang J, Kane J, Correll C
Schizophr Res. 2012; 138(1):18-28.
PMID: 22534420
PMC: 3382997.
DOI: 10.1016/j.schres.2012.03.018.
Electroencephalographic abnormalities in clozapine-treated patients: a cross-sectional study.
Goyal N, Praharaj S, Desarkar P, Nizamie H
Psychiatry Investig. 2012; 8(4):372-6.
PMID: 22216049
PMC: 3246147.
DOI: 10.4306/pi.2011.8.4.372.
Obsessive-compulsive symptoms in chronic schizophrenia: a new idea or an old belief?.
Jaydeokar S, Gore Y, Diwan P, Deshpande P, Desai N
Indian J Psychiatry. 2011; 39(4):324-8.
PMID: 21584101
PMC: 2967167.
A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.
Honer W, Procyshyn R, Chen E, MacEwan G, Barr A
J Psychiatry Neurosci. 2009; 34(6):433-42.
PMID: 19949719
PMC: 2783434.
The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders.
Ungvari G, Caroff S, Gerevich J
Schizophr Bull. 2009; 36(2):231-8.
PMID: 19776208
PMC: 2833122.
DOI: 10.1093/schbul/sbp105.
Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study.
Broekema W, de Groot I, van Harten P
Pharm World Sci. 2007; 29(3):126-30.
PMID: 17333501
PMC: 1915627.
DOI: 10.1007/s11096-006-9063-1.
A case study evaluating the use of clozapine in depression with psychotic features.
Jeyapaul P, Vieweg R
Ann Gen Psychiatry. 2006; 5:20.
PMID: 17134508
PMC: 1693912.
DOI: 10.1186/1744-859X-5-20.
Augmentation strategies in clozapine-resistant schizophrenia.
Remington G, Saha A, Chong S, Shammi C
CNS Drugs. 2005; 19(10):843-72.
PMID: 16185094
DOI: 10.2165/00023210-200519100-00004.
Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.
Moller H
Eur Arch Psychiatry Clin Neurosci. 2005; 255(2):83-93.
PMID: 15812601
DOI: 10.1007/s00406-005-0580-z.
Low doses of clozapine may stabilize treatment-resistant bipolar patients.
Fehr B, Ozcan M, Suppes T
Eur Arch Psychiatry Clin Neurosci. 2004; 255(1):10-4.
PMID: 15538596
DOI: 10.1007/s00406-004-0528-8.